The emergence of new treatment options for DLBCL means better response rates and long-term survival, and ultimately, more hope for patients SSD has tracked eight DLBCL treatments since July 2022 up to sixteen treatments in January 2025, and whilst at a national level we see three dominant regimens being used to treat approximately 70% of DBLCL patients, there is considerable variation at NHS Trust level.